US Pharma MarketingWith $30M launch, Oorja Bio breathes new life into South Korean fibrosis candidate
With $30M launch, Oorja Bio breathes new life into South Korean fibrosis candidate is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
In the sprawling metropolis of Houston, a new biotech has emerged to tackle the biology underlying a lung disease that has no clear cause. Oorja Bio launched yesterday afternoon with $30 million and an in-licensed, novel approach to treat idiopathic pulmonary fibrosis.
Source: FierceBiotech